![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCNA1 |
Gene summary for CCNA1 |
![]() |
Gene information | Species | Human | Gene symbol | CCNA1 | Gene ID | 8900 |
Gene name | cyclin A1 | |
Gene Alias | CT146 | |
Cytomap | 13q13.3 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A140VJG0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8900 | CCNA1 | LZE4T | Human | Esophagus | ESCC | 1.39e-20 | 9.22e-01 | 0.0811 |
8900 | CCNA1 | LZE7T | Human | Esophagus | ESCC | 2.07e-09 | 5.56e-01 | 0.0667 |
8900 | CCNA1 | P5T-E | Human | Esophagus | ESCC | 1.52e-08 | 3.29e-01 | 0.1327 |
8900 | CCNA1 | P9T-E | Human | Esophagus | ESCC | 3.67e-14 | 3.77e-01 | 0.1131 |
8900 | CCNA1 | P15T-E | Human | Esophagus | ESCC | 1.35e-04 | 2.17e-01 | 0.1149 |
8900 | CCNA1 | P22T-E | Human | Esophagus | ESCC | 2.85e-04 | 3.02e-01 | 0.1236 |
8900 | CCNA1 | P24T-E | Human | Esophagus | ESCC | 2.51e-20 | 9.78e-01 | 0.1287 |
8900 | CCNA1 | P28T-E | Human | Esophagus | ESCC | 4.67e-07 | 4.70e-01 | 0.1149 |
8900 | CCNA1 | P30T-E | Human | Esophagus | ESCC | 9.20e-05 | 2.21e-01 | 0.137 |
8900 | CCNA1 | P36T-E | Human | Esophagus | ESCC | 2.11e-03 | 4.16e-01 | 0.1187 |
8900 | CCNA1 | P37T-E | Human | Esophagus | ESCC | 4.27e-06 | 1.62e-01 | 0.1371 |
8900 | CCNA1 | P74T-E | Human | Esophagus | ESCC | 4.76e-19 | 8.06e-01 | 0.1479 |
8900 | CCNA1 | P83T-E | Human | Esophagus | ESCC | 2.25e-31 | 1.39e+00 | 0.1738 |
8900 | CCNA1 | P89T-E | Human | Esophagus | ESCC | 5.33e-06 | 5.97e-01 | 0.1752 |
8900 | CCNA1 | P91T-E | Human | Esophagus | ESCC | 4.77e-11 | 1.25e+00 | 0.1828 |
8900 | CCNA1 | P107T-E | Human | Esophagus | ESCC | 4.56e-28 | 9.99e-01 | 0.171 |
8900 | CCNA1 | P130T-E | Human | Esophagus | ESCC | 2.05e-04 | 4.82e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa05169210 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa0516510 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa051619 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa052215 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0415210 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0516937 | Esophagus | ESCC | Epstein-Barr virus infection | 151/4205 | 202/8465 | 1.55e-13 | 3.45e-12 | 1.77e-12 | 151 |
hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
hsa0516515 | Esophagus | ESCC | Human papillomavirus infection | 215/4205 | 331/8465 | 7.86e-09 | 7.12e-08 | 3.65e-08 | 215 |
hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
hsa0516114 | Esophagus | ESCC | Hepatitis B | 108/4205 | 162/8465 | 7.68e-06 | 4.15e-05 | 2.12e-05 | 108 |
hsa0522113 | Esophagus | ESCC | Acute myeloid leukemia | 49/4205 | 67/8465 | 7.43e-05 | 3.07e-04 | 1.57e-04 | 49 |
hsa0415213 | Esophagus | ESCC | AMPK signaling pathway | 80/4205 | 121/8465 | 1.73e-04 | 6.67e-04 | 3.42e-04 | 80 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCNA1 | SNV | Missense_Mutation | novel | c.16N>T | p.Pro6Ser | p.P6S | P78396 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CCNA1 | SNV | Missense_Mutation | c.1220C>A | p.Thr407Asn | p.T407N | P78396 | protein_coding | tolerated(0.12) | benign(0.068) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
CCNA1 | insertion | Nonsense_Mutation | novel | c.545_546insGATACATATGTGAGGTAGATTAAAATTTTAGG | p.Ser183IlefsTer4 | p.S183Ifs*4 | P78396 | protein_coding | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | ||
CCNA1 | deletion | In_Frame_Del | c.301_309delNNNNNNNNN | p.Thr102_Ile104del | p.T102_I104del | P78396 | protein_coding | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |||
CCNA1 | SNV | Missense_Mutation | c.280N>T | p.Arg94Trp | p.R94W | P78396 | protein_coding | deleterious(0.01) | possibly_damaging(0.781) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
CCNA1 | SNV | Missense_Mutation | rs748235047 | c.1075N>A | p.Val359Ile | p.V359I | P78396 | protein_coding | tolerated(0.28) | benign(0.005) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCNA1 | SNV | Missense_Mutation | c.108G>T | p.Gln36His | p.Q36H | P78396 | protein_coding | tolerated_low_confidence(0.12) | benign(0.146) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
CCNA1 | SNV | Missense_Mutation | c.754N>T | p.Val252Leu | p.V252L | P78396 | protein_coding | deleterious(0) | possibly_damaging(0.489) | TCGA-AA-3506-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CCNA1 | SNV | Missense_Mutation | c.38N>T | p.Ser13Phe | p.S13F | P78396 | protein_coding | deleterious_low_confidence(0.04) | benign(0.205) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CCNA1 | SNV | Missense_Mutation | c.50N>A | p.Gly17Asp | p.G17D | P78396 | protein_coding | tolerated_low_confidence(0.1) | benign(0.017) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |